strategy to achieve this includes:•Focus on the highly attractive, expanding market for protein detection and analysis;•Continue to drive adoption of the Simoa platform in the research, diagnostics and precision health screening markets;•Leverage the Simoa "ecosystem" to grow our customer base and further penetrate our existing customer base;•Utilize the flexibility of the Simoa platform to expand into complementary markets, including nucleic acid detection;•Leverage the data generated by Simoa to drive adoption of our technology; and•Grow into new markets organically with our customers and through strategic collaborations.7Table of ContentsRisks related to our businessInvesting in our common stock involves substantial risk.
harmed;•Our future capital needs are uncertain and we may need to raise additional funds in the future;•If our products fail to achieve and sustain sufficient market acceptance, our revenue will be adversely affected;•Our future success is dependent upon our ability to further penetrate our existing customer base and attract new customers;•Some of the reagents used in our products are labeled "research use only" and will have to undergo additional testing before we could use them
and biopharmaceutical companies, a reduction in which could limit demand for our products and adversely affect our business and operating results;•If we do not successfully develop and introduce new assays for our technology, we may not generate new sources of revenue and may not be able
use, we will be required to obtain regulatory clearance(s) or approval(s), and any such regulatory process would be expensive, time-consuming, and uncertain both in timing and in outcome;•If we are unable to protect our intellectual property, it may reduce our ability to maintain any technological or competitive advantage over
customers in the United States and internationally; (2) to improve and update our Simoa technology and instruments and to develop additional assays, including assays for nucleic acid detection; (3) to support the launch of our new Quanterix
manufacturing footprint; (5) to pursue regulatory approvals or clearances to develop instruments, assay kits and consumables in areas outside of life science research, including potentially LDTs, IVD tests and other markets, and, subject to the
that should be expected in the future.Consolidated statement of operations data (in thousands, except per share data)​​​​​​​​​​​​​​Year endedDecember 31Nine monthsended September 302015201620162017​​​​​​​​​​​​​​(unaudited)Total revenue$12,180$17,585$10,906$16,285Cost of revenue6,4659,8376,7469,179Research and development10,08316,99310,19212,377Selling, general and administrative10,15512,4668,86613,641​​​​​​​​​​​​​​Total operating expenses26,70339,29625,80435,197​​​​​​​​​​​​​​Loss from operations(14,523)(21,711)(14,898)(18,912)Interest expense, net(1,040)(1,298)(1,012)(735)Other income (expense), net(380)(164)5110​​​​​​​​​​​​​​Net loss(15,943)(23,173)(15,859)(19,637)Accretion and accrued dividends on redeemable convertible preferred stock(4,355)(4,445)(3,325)(3,349)​​​​​​​​​​​​​​Net loss attributable to common stockholders$(20,298)$(27,618)$(19,184)$(22,986)​​​​​​​​​​​​​​Net loss per share attributable to common stockholders, basic and diluted$(11.19)$(12.89)$(9.09)$(9.51)​​​​​​​​​​​​​​Weighted-average common shares outstanding1,8132,1432,1102,417​​​​​​​​​​​​​​13Table of ContentsConsolidated balance sheet data (in thousands)​​​​​​​​​​​As of September 30, 2017ActualPro forma(1)Pro formaas adjusted(2)​​​​​​​​​​​(unaudited)Cash and cash equivalents$18,690$18,690$62,543Total assets30,51530,51574,368Total long term debt9,3289,3289,328Total redeemable convertible preferred stock142,387——Total stockholders' (deficit) equity(136,544)6,62450,477​​​​​​​​​​​(1)    The
The quality of our products and services may suffer, which could negatively affect our reputation and harm our ability to retain and attract customers.Our future capital needs are uncertain and we may need to raise additional funds in the future.We believe that the net proceeds from this offering, together with our cash generated from commercial sales and our existing cash and cash equivalents as of
"Business—Government regulation—Clinical trials" for further information about the FDA approvals that we may be required to seek and obtain in that circumstance);•lease a larger facility or build out our existing facility as we continue to grow our employee headcount;•hire additional personnel;•enter into collaboration arrangements, if any, or in-license other products and technologies;•add operational, financial and management information systems; and•incur increased costs as a result of operating as a public company.Our
future funding requirements will depend on many factors, including:•market acceptance of our products, including our Quanterix SR-X instrument that we expect to launch commercially in 2018;•the cost and timing of establishing additional sales, marketing and distribution capabilities;•the cost of our research and development activities;•the success of our existing collaborations and our ability to enter into additional collaborations in the future; and•the effect of competing technological and market developments.We
Any such additional testing may be expensive and time-consuming and delay our introduction of new products and systems.In the near term, our business will depend on levels of research and development spending by academic and governmental research institutions and biopharmaceutical companies, a
reduction in which could limit demand for our products and adversely affect our business and operating results.In the near term, we expect that our revenue will be derived primarily from sales of our instruments and consumables to academic and governmental research
of biomarkers in a single sample, we could lose revenue opportunities with existing or future customers.If we do not successfully manage the development and launch of new products, our financial results could be adversely affected.We expect to launch our Quanterix SR-X instrument in 2018.
they may never result in the successful development or commercialization of products based on our Simoa technology.Our reliance on distributors for sales of our products outside of the United States could limit or prevent us from selling our products and could impact our revenue.We have established exclusive distribution agreements for our Simoa HD-1 Analyzer and related consumable products within Australia, China, India, Japan,
proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms, if at all.Our issued patents could be found invalid or unenforceable if challenged in court, which could have a material adverse impact on our business.If we or any of our partners were to initiate legal proceedings against a third-party to enforce a patent covering one of our products or services, the
other customers without a license.We may not be able to protect our intellectual property rights throughout the world, which could materially, negatively affect our business.Filing, prosecuting and defending patents on current and future products in all countries throughout the world would be prohibitively expensive, and our
collaborations, commercial relationships or capital commitments;•competition from existing products or new products that may emerge;•failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;•issuance of new or updated research or reports by securities analysts or recommendations for our stock;•adverse regulatory announcements;•disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent
protection for our technologies;•commencement of, or our involvement in, litigation;•fluctuations in the valuation of companies perceived by investors to be comparable to us;•market conditions in our markets;•manufacturing disputes or delays;•any future sales of our common stock or other securities;•any change to the composition of the board of directors or key personnel;•expiration of contractual lock-up agreements with our executive officers, directors and security holders;43Table of Contents•general economic conditions and slow or negative growth of our markets;•share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;•announcement or expectation of additional debt or equity financing efforts; and•other factors described in this section of the prospectus.Further,